Magnesium prophylaxis for prevention of cisplatin induced nephrotoxicity

Author

Lu Mao

Published

May 5, 2026

Statistical analysis

Results

Table 1: Baseline demographics of patients receiving cisplatin chemotherapy
Characteristic F
N = 281		 M
N = 601		 Overall
N = 881
Age 72 (63, 77) 54 (36, 69) 63 (42, 73)
Race


    White 27 (96%) 57 (95%) 84 (95%)
    Black 1 (3.6%) 1 (1.7%) 2 (2.3%)
    American Indian or Alaskan Native 0 (0%) 1 (1.7%) 1 (1.1%)
    Asian 0 (0%) 1 (1.7%) 1 (1.1%)
Ethnicity


    Hispanic/Latino 3 (11%) 4 (6.7%) 7 (8.0%)
    Not Hispanic or Latino 25 (89%) 56 (93%) 81 (92%)
Baseline Serum Creatinine (mg/dL) 0.72 (0.57, 0.85) 0.85 (0.72, 1.02) 0.81 (0.70, 1.00)
Baseline Creatinine Clearance (mL/min) 88 (65, 118) 117 (86, 149) 108 (78, 147)
1 Median (Q1, Q3); n (%)